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Abstract
There is a striking paradox in the literature supporting high-profile
measures to reduce ventilator-associated pneumonia (VAP): many
studies show significant reductions in VAP rates but almost none
show any impact on patients’ duration of mechanical ventilation,
length of stay in the intensive care unit and hospital, or mortality.
The paradox is largely attributable to lack of specificity in the VAP
definition. The clinical and microbiological criteria for VAP capture
a population of patients with an array of conditions that range from
serious to benign. Many of the benign events are manifestations of
bacterial colonization superimposed upon pulmonary edema,
atelectasis, or other non-infectious processes. VAP prevention
measures that work by decreasing bacterial colonization
preferentially lower the frequency of these mislabelled, more
benign events. In addition, misclassification obscures detection of
an impact of prevention measures on bona fide pneumonias.
Together, these effects create the possibility of the paradox where
a prevention measure may have a large impact on VAP rates but
minimal impact on patients’ outcomes. The paradox makes
changes in VAP rates alone an unreliable measure of whether VAP
prevention measures are truly beneficial to patients and behooves
us to measure their impact on patient outcomes before advocating
their adoption.
The paradox
Hospitals around the world are striving to reduce their rates
of ventilator-associated pneumonia (VAP) in order to improve
patient outcomes and minimize costs. Professional societies,
legislators, quality improvement advocates, and medical
product manufacturers are promoting an increasing array of
interventions to reduce VAP rates. These include regular oral
care, elevation of the head of the bed, continuous aspiration
of subglottic secretions, silver-coated endotracheal tubes,
and many other initiatives. Some jurisdictions now mandate
hospitals to report adherence with a subset of these ‘process
measures’. Review of the literature supporting these
interventions, however, reveals a striking paradox: each of
these strategies dramatically reduces VAP rates but almost
none has any impact on patients’ duration of mechanical
ventilation, hospital length of stay, or mortality (Table 1).
Regular oral care with chlorhexidine, for example, reduces
VAP rates by up to 37% to 66% but has no impact on
duration of mechanical ventilation, intensive care unit (ICU) or
hospital length of stay, or mortality [1-4]. Likewise, elevation
of the head reduces the VAP rate by 78% [5], continuous
aspiration of subglottic secretions reduces VAP rates by
50% to 55% [6,7], and silver-coated endotracheal tubes
decrease VAP rates by 36% [8]. None of these investiga-
tions, though, showed an impact on patients’ outcomes.
Many of these studies were not primarily powered to detect a
difference in length of stay or mortality, but it is striking that
they did not even show trends toward improvements in these
outcomes regardless of whether considered alone or in meta-
analyses that included thousands of patients [4,9,10]. The
failure of these studies to detect an impact on patient
outcomes is conspicuous since the balance of research does
show that VAP doubles the risk of dying and increases
intensive care length of stay by a mean of 6 days [11].
The explanation
The source of this paradox lies in the ambiguity and
inaccuracy inherent in VAP diagnosis. VAP is typically defined
as the presence of fever, abnormal white blood cell count,
purulent sputum, and new radiographic infiltrates. On
intensive investigation, however, only a fraction of patients
with these signs truly have histological pneumonia [12].
Instead, up to two thirds of people who fulfill this definition
have one or more alternative conditions that range from
relatively benign, such as atelectasis and tracheobronchitis,
to severe, such as acute respiratory distress syndrome or
pulmonary infarction [13,14].
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Table 1
Randomized controlled trials of interventions to prevent ventilator-associated pneumonia
Impact on
Subjects VAP rates Ventilator LOS ICU LOS Hospital LOS Mortality
Elevation of the head of the bed
Drakulovic, et al., 1999 [5] 86 78% ↓ NS NS - NS
van Nieuwenhoven, et al., 2006 [46] 221 NS NS NS - NS
Oral care
Chlorhexidine
DeRiso, et al., 1996 [40]  353 NS NS - NS 80% ↓
Fourrier, et al., 2000 [1] 60 66% ↓ NS NS - NS
Genuit, et al., 2001 [2]  95 37% ↓ NS NS NS -
Houston, et al., 2002 [47]  561 NS NS - - -
Fourrier, et al., 2005 [48] 228 NS NS NS - NS
Koeman, et al., 2006 [3] 257 NS NS NS NS NS
Segers, et al., 2006 [49] 954 50% ↓ - NS 8% ↓ NS
Tantipong, et al., 2008 [50] 207 NS - - - NS
Chan, et al., 2007 [4] (meta-analysis) 2,144 44% ↓ NS NS - NS
Oral topical antibiotics
Laggner, et al., 1994 [51] (gentamicin) 67 NS NS - - NS
Bergmans, et al., 2001 [52]  226 57%-68% ↓ NS NS NS NS
(gentamicin, colistin, vancomycin) 
Kollef, et al., 2006 [53] (iseganan) 709 NS - - - NS
Chan, et al., 2007 [4] (meta-analysis) 1,098 NS NS NS - NS
de Smet, et al., 2009 [31]  3,894 - NS NS NS 14% ↓
(tobramycin, colistin, amphotericin B)
Deep vein thrombosis prophylaxis
Samama, et al., 1999 [54] 1,102 - - - - NS
Fraisse, et al., 2000 [55] 223 - - - - NS
Leizorovicz, et al., 2004 [56] 3,706 - - - - NS
Mahé, et al., 2005 [57] 2,474 - - - - NS
Stress ulcer prophylaxis
Prod’hom, et al., 1994 [58] 248 NS - - - NS
Bonten, et al., 1995 [59] 141 NS - - NS NS
Yildizdas, et al., 2002 [60] 160 NS - - - NS
Kantorova, et al., 2004 [61] 287 NS NS NS - NS
Cook, et al., 1996 [10] (meta-analysis) 7,218 NS - - - NS
Continuous aspiration of subglottic secretions
Valles, et al., 1995 [6] 153 37% ↓ -N S-N S
Kollef, et al., 1999 [62] 343 39% ↓ NS NS NS NS
Smulders, et al., 2002 [63] 150 75% ↓ NS NS NS NS
Lorente, et al., 2007 [64] 280 64% ↓ NS NS - NS
Bouza, et al., 2008 [39] 690 NS NS NS NS NS
Silver-coated endotracheal tubes
Kollef, et al., 2008 [8] 2,003 36% ↓ NS NS NS NS
ICU, intensive care unit; LOS, length of stay; NS, not statistically significant; VAP, ventilator-associated pneumonia; Ventilator LOS, duration of
mechanical ventilation.The addition of microbiological criteria does little to improve
accuracy. Many studies define VAP as the presence of
greater than 1,000 colony-forming units per milliliter on culture
of bronchoalveolar lavage fluid. This definition is attractive
because it is objective, but unfortunately it is no more
accurate than clinical criteria alone [15]. The sensitivity and
specificity of this definition relative to a histological gold
standard are only 50%-70% and 40%-95%, respectively
[16-19]. False positives are due to contamination of the
lavage specimen by bacteria colonizing the patient’s
endotracheal tube and upper airway. This effect is particularly
marked in patients with prolonged ventilation. False negatives
arise from the failure to sample the correct lung segment,
insufficient bacterial growth to cross the quantitative
threshold, and damping of bacterial growth by prior antibiotic
exposure.
Much of VAP misdiagnosis stems from bacterial colonization
superimposed upon non-infectious pulmonary processes
such as fluid shifts, barotrauma, atelectasis, inflammatory
reactions, and exacerbations of patients’ underlying lung
disease. These factors wax and wane in ways that are difficult
to discern at the bedside, leading to the transient appearance
of clinical syndromes suggestive of VAP. As often as not,
these processes spontaneously resolve in short order without
definitive therapy. Clinical trials for early empiric treatment of
suspected VAP followed by reassessment 48 to 72 hours
later hint at this process. In many patients, the VAP syndrome
is no longer present on reassessment and antibiotics can
safely be stopped without discernible impact on patient
outcomes [20-22].
Mislabelling benign events as VAP creates bias if prevention
measures preferentially affect the more benign disorders
over the more serious disorders present within the spectrum
of conditions that look like VAP. This is particularly likely in
studies that use a microbiological definition of VAP to
assess interventions that work by decreasing bacterial
colonization of the endotracheal tube. For example, the
NASCENT (North American Silver-Coated Endotracheal
Tube) study of silver-coated endotracheal tubes compared
with conventional endotracheal tubes found a statistically
significant 36% reduction in microbiologically confirmed
VAP yet no difference in the rate of physician-suspected
VAP (26% versus 31%, P = 0.39) or patients with radio-
graphic infiltrates and suggestive clinical signs (53% versus
56%,  P = 0.74) [8]. This discrepancy between rates of
microbiologically defined VAP versus clinically defined VAP
suggests that silver-coated tubes preferentially decrease
colonization rather than infection. This is further borne out by
identical durations of mechanical ventilation, ICU stay,
hospital stay, and mortality between patients with silver-
coated versus conventional tubes. Other interventions that
decrease microbial colonization, such as oral chlorhexidine
and continuous aspiration of subglottic secretions, might
also be subject to this bias.
Mislabelling benign events as VAP further contributes to the
paradox by obscuring faint but true signals from bona fide
pneumonias. Some interventions designed to prevent VAP
may well reduce the frequency of bona fide pneumonias (and
truly improve outcomes for this subset of patients), but the
plethora of alternative conditions captured by the VAP
definition dilute the signal coming from the subset of patients
with true pneumonias. Generally low event rates in both the
intervention and control groups of many studies compound
the challenge of detecting significant impacts on outcomes.
These effects may also explain some of the conflicting results
in studies evaluating the attributable mortality of VAP: the
failure of some studies to detect an impact on mortality [23-
26] despite a statistically significant impact in other studies
[27-29] and on meta-analysis [11] may be due to damping of
the ‘true’ VAP morbidity signal by misclassifying relatively
benign conditions as VAP. Alternatively, VAP may be more of
a marker for severity of illness in intubated patients rather
than an independent source of morbidity in and of itself.
Either way, the failure of multiple clinical trials to detect an
impact of VAP prevention measures on patient outcomes
suggests that the net benefit of these interventions on the
population level is small.
The implication
The near impossibility of accurate VAP diagnosis compels us
to exert great caution when interpreting trial data and hospital
surveillance data showing decreases in VAP rates. Lower
rates in the intervention arm of clinical trials may reflect dis-
proportionate decreases in benign mimickers of VAP rather
than VAP itself. Similarly, observational reports of markedly
reduced VAP rates in some hospitals may reflect measure-
ment artefact more than true reductions in serious disease
[14]. Before advocating their adoption, we need to see that
new interventions and quality improvement programs impact
meaningful outcomes rather than just VAP rates.
Likewise, legislators considering mandatory reporting of VAP
prevention process measures should consider their impact on
outcomes before compelling implementation. Due to the
inaccuracy and ambiguity in surveillance definitions, many
jurisdictions have shied away from requiring VAP reporting
[14,30]. It will be a great irony if these jurisdictions now
compel hospitals to report VAP prevention process measures
validated by studies that used the same imperfect VAP
definitions to prove their value yet failed to show any impact
on patient outcomes.
Clinicians and patients can take heart that some interventions
have been shown to improve hard outcomes and do merit
adoption. Selective oropharyngeal decontamination reduces
ICU patients’ mortality [31]. Likewise, daily sedative interrup-
tions and daily assessments of readiness to extubate
consistently reduce patients’ duration of mechanical ventila-
tion and possibly lower mortality (Table 2) [32-38]. Other
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[39,40] but this outcome has not yet been widely studied.
There is also tentative evidence that combining interventions
into bundles may impact patient outcomes even when the
component interventions alone do not. Ventilator bundles
typically include elevating the head of the bed, stress ulcer
prophylaxis, thromboembolism prophylaxis, and a daily
weaning assessment. None of these measures in isolation
has been shown to decrease patients’ length of stay, yet
three centers implementing these measures as a bundle
reported shorter ICU lengths of stay [41-43] and a fourth
center found shorter hospital length of stay [44] compared
with historical rates. These studies, while promising, need to
be interpreted with great caution since they suffer many
methodological limitations, including the use of historical
rather than concurrent controls [45].
For too long, we have accepted VAP as a surrogate marker
for the outcomes we really care about, namely patients’
duration of mechanical ventilation, hospital length of stay, and
mortality. The disparity between prevention measures’ impact
on VAP rates and their lack of impact on patient outcomes
underscores the inadequacy of VAP as a surrogate marker.
We need to directly assess the impact of VAP prevention
measures on patient outcomes before advocating or
compelling their adoption.
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